Standard of Care: Initial Treatment & Surgery

For early-stage ER-positive (ER+) / HER2-negative breast cancer, treatment is a carefully timed sequence designed to remove the cancer now and prevent it from returning years later. While surgery is the first step for most people, the “standard of care” has shifted toward doing only as much as is necessary to ensure safety while preserving your quality of life ^[1][2].

Choosing Your Surgery: Lumpectomy vs. Mastectomy

The primary goal of surgery is to remove the tumor with a “clear margin”—a surrounding layer of healthy tissue that contains no cancer cells ^[3].

• Breast-Conserving Surgery (Lumpectomy): This involves removing the tumor and a small amount of surrounding tissue. For most patients with early ER+ cancer, a lumpectomy followed by radiation provides the same long-term survival as a mastectomy ^[1].
• Mastectomy: This is the removal of the entire breast. It may be recommended if the tumor is very large relative to the breast, if there are multiple tumors in different areas (multifocal), or if you have a genetic mutation (like BRCA) that increases your risk of a second cancer. A BRCA mutation or multifocal disease does not automatically require mastectomy, and importantly, a mastectomy does not always avoid radiation, particularly with positive nodes or large tumors ^[1].

Shrinking the Tumor Before Surgery

In some cases, your doctor may suggest Neoadjuvant Therapy—treatment given before surgery.

• Neoadjuvant Endocrine Therapy (NET): For postmenopausal women with strongly ER+ tumors, taking an aromatase inhibitor for 3 to 6 months can shrink a tumor enough to allow for a lumpectomy instead of a mastectomy ^[4][5].
• Neoadjuvant Chemotherapy: This choice is usually driven by stage, tumor biology (including HER2 status, high grade, or advanced stage), operability, and the need for rapid downstaging, rather than relying solely on an adjuvant genomic assay ^[6][7].

Managing the Lymph Nodes

To see if the cancer has begun to spread, surgeons typically perform a Sentinel Lymph Node Biopsy (SLNB), removing the first few “gatekeeper” nodes in the armpit ^[2].

However, we are learning that not everyone needs this procedure. Current guidelines (such as those from the Society of Surgical Oncology) suggest that SLNB can be safely omitted in women aged 70 or older who have small, clinically node-negative, ER+ tumors and plan to take hormone therapy ^[8][9]. In these highly selected cases, the risk of a dangerous recurrence in the armpit is so low that the surgery—and its risk of side effects like lymphedema (swelling)—may not be necessary ^[10][11]. For instance, a 55-year-old with a T2 tumor does not fit this group; SLNB is commonly part of surgery for this profile and influences later treatment decisions.

Radiation: When Can It Be Skipped?

Following a lumpectomy, radiation is usually recommended to kill any microscopic cancer cells left behind. However, for older patients with low-risk ER+ cancer, radiation is now an area of “shared decision-making.”

Data from the PRIME II trial showed that for women aged 65 or older with small (under 3cm), node-negative ER+ tumors, omitting radiation did not affect overall survival ^[12]. While the risk of the cancer coming back in the same breast was higher (about 9.5% without radiation vs. 0.9% with radiation after 10 years), the risk of the cancer spreading to other parts of the body remained the same ^[12][13].

For very low-risk “Luminal A” tumors (identified by a strict Ki-67 threshold), the LUMINA study similarly found that skipping radiation may be a safe option if the patient is committed to long-term hormone therapy ^[14].

It is crucial to note that these omission studies involve highly selected older populations. For a 55-year-old with a T2 (e.g. 2.5 cm) tumor, these data do not establish that radiation can be safely omitted, and a lumpectomy is generally followed by radiation.

The Typical Treatment Sequence

In ER+ breast cancer, your sequence is individualized and branches based on pathology. A common flow looks like this:

1. Surgery: The tumor and (usually) sentinel nodes are removed.
2. Pathology & Genomics: Your team reviews the final report and may order a genomic test (like Oncotype DX) to decide if chemotherapy is needed ^[15].
3. Chemotherapy: If recommended, this is usually given after surgery but before radiation ^[16].
4. Radiation: Typically begins after you have recovered from surgery (or finished chemotherapy) ^[16].
5. Endocrine Therapy: This is the “foundation” of your long-term care. It usually starts after radiation is complete (or sometimes concurrently) and continues for 5 to 10 years ^[17][18].

By following this customized sequence, your care team addresses the cancer from every angle—locally with surgery and radiation, and systemically with hormone therapy and, if needed, chemotherapy.